MARKET

FENC

FENC

Fennec Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.82
-0.26
-4.28%
Pre Market: 5.82 0 0.00% 06:27 09/24 EDT
OPEN
6.09
PREV CLOSE
6.08
HIGH
6.16
LOW
5.79
VOLUME
193.31K
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.200
MARKET CAP
147.57M
P/E (TTM)
-8.6633
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Fennec Announces Issuance Of US Patent For PEDMARK
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation
Benzinga · 3d ago
Fennec Announces Issuance of U.S. Patent for PEDMARK™
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric
GlobeNewswire · 3d ago
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Fennec Pharmaceuticals Inc.
The law firm of Kirby McInerney LLP is investigating potential claims against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC). The investigation concerns whether Fennec and certain of its officers and/or directors have engaged in securities fraud or other unlawful
Business Wire · 08/19 01:00
FENNEC ALERT: Bragar Eagel & Squire, P.C. is Investigating Fennec Pharmaceuticals, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Business Wire · 08/18 19:41
EQUITY ALERT: ROSEN, A LEADING AND RANKED FIRM, Announces Investigation of Securities Claims Against Fennec Pharmaceuticals Inc. FENC
Business Wire · 08/17 15:54
Mid-Afternoon Market Update: Dow Rises 1%; Kforce Shares Climb On Upbeat Q2 Results
Toward the end of trading Tuesday, the Dow traded up 1.06% to 28085.22 while the NASDAQ fell 0.22% to 10,944.77. The S&P also rose, gaining 0.45% to 3,375.46.
Benzinga · 08/11 18:40
Mid-Day Market Update: Gold Plunges Over 4%; Pfenex Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.97% to 28061.49 while the NASDAQ fell 0.19% to 10,947. The S&P also rose, gaining 0.35% to 3,372.07.
Benzinga · 08/11 16:11
Mid-Morning Market Update: Markets Mostly Higher; SYSCO Reports Q2 Loss
Following the market opening Tuesday, the Dow traded up 1.06% to 28,085.34 while the NASDAQ fell 0.57% to 10,905.91. The S&P also rose, gaining 0.26% to 3,369.12.
Benzinga · 08/11 14:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FENC. Analyze the recent business situations of Fennec Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FENC stock price target is 15.00 with a high estimate of 21.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 16.22M
% Owned: 63.98%
Shares Outstanding: 25.36M
TypeInstitutionsShares
Increased
18
3.25M
New
36
1.31M
Decreased
4
25.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
Khalid Islam
Chief Executive Officer/Director
Rostislav Raykov
Chief Financial Officer
Robert Andrade
Other
Shubh Goel
Independent Director
Marco Brughera
Independent Director
Jodi Cook
Independent Director
Adrian Haigh
Independent Director
Chris Rallis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FENC
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fennec Pharmaceuticals Inc stock information, including NASDAQ:FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.